Evidence map›Paper›PMID 23099443›Full record

ArticleJournal of lipid research2013

Specific Kv1.3 blockade modulates key cholesterol-metabolism-associated molecules in human macrophages exposed to ox-LDL.

Yong Yang, Yan-Fu Wang, Xiao-Fang Yang, Zhao-Hui Wang, Yi-Tian Lian, Ying Yang, Xiao-Wei Li, Xiang Gao, Jian Chen, Yan-Wen Shu and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of lipid research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Functional Potassium Channels in Macrophages.The Journal of membrane biology · 2023
    Review
  4. Discovery of KMedicinal research reviews · 2021
    Review
  5. Review
  6. Article
  7. Mechanisms of foam cell formation in atherosclerosis.Journal of molecular medicine (Berlin, Germany) · 2017
    Review
  8. Macrophage-mediated cholesterol handling in atherosclerosis.Journal of cellular and molecular medicine · 2016
    Review
  9. Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance.Proceedings of the National Academy of Sciences of the United States of America · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Yong YangDepartment of Cardiology, Union Hospital, Huazhong University of Science and Technology, Wuhan, China.
Yan-Fu Wang
Xiao-Fang Yang
Zhao-Hui Wang
Yi-Tian Lian
Ying Yang
Xiao-Wei Li
Xiang Gao
Jian Chen
Yan-Wen Shu
Long-Xian Cheng
Yu-Hua Liao
Kun Liu
Huazhong University of Science and Technology · CNJining Medical University · CNTianjin Chest Hospital · CNTongji Hospital · CNUnion Hospital · CNWuhan Union Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cholesterol-metabolism-associated molecules, including scavenger receptor class A (SR-A), lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), CD36, ACAT1, ABCA1, ABCG1, and scavenger receptor class B type I, can modulate cholesterol metabolism in the transformation from macrophages to foam cells. Voltage-gated potassium channel Kv1.3 has increasingly been demonstrated to play an important role in the modulation of macrophage function. Here, we investigate the role of Kv1.3 in modulating cholesterol-metabolism-associated molecules in human acute monocytic leukemia cell-derived macrophages (THP-1 macrophages) and human monocyte-derived macrophages exposed to oxidized LDL (ox-LDL). Human Kv1.3 and Kv1.5 channels (hKv1.3 and hKv1.5) are expressed in macrophages and form a heteromultimeric channel. The hKv1.3-E314 antibody that we had generated as a specific hKv1.3 blocker inhibited outward delayed rectifier potassium currents, whereas the hKv1.5-E313 antibody that we had generated as a specific hKv1.5 blocker failed. Accordingly, the hKv1.3-E314 antibody reduced percentage of cholesterol ester and enhanced apoA-I-mediated cholesterol efflux in THP-1 macrophages and human monocyte-derived macrophages exposed to ox-LDL. The hKv1.3-E314 antibody downregulated SR-A, LOX-1, and ACAT1 expression and upregulated ABCA1 expression in THP-1 macrophages and human monocyte-derived macrophages. Our results reveal that specific Kv1.3 blockade represents a novel strategy modulating cholesterol metabolism in macrophages, which benefits the treatment of atherosclerotic lesions.

Indexed as

Antibody SpecificityAcetyl-CoA C-AcetyltransferaseApolipoprotein A-IATP Binding Cassette Transporter 1ATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily G, Member 1Biological TransportCD36 AntigensCell LineCell MembraneCholesterolElectrophysiological PhenomenaGene Expression RegulationHumansKv1.3 Potassium ChannelKv1.5 Potassium ChannelABCA1 protein, humanABCG1 protein, humanACAT1 protein, humanAcetyl-CoA C-AcetyltransferaseApolipoprotein A-IATP Binding Cassette Transporter 1ATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily G, Member 1CD36 AntigensCholesterolKv1.3 Potassium ChannelKv1.5 Potassium ChannelLipoproteins, LDLOLR1 protein, humanoxidized low density lipoproteinPotassiumScavenger Receptors, Class AScavenger Receptors, Class E

Identifiers

PMID23099443
PMCPMC3520537
OpenAlexW2142914412

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.